EssilorLuxottica S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Francesco Milleri
- Full Time Employees
- 153,498
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1-5 rue Paul CEzanne Paris France 75008
- IPO Date
- Jan 30, 2008
- CIK
- 0001085922
- Website
- essilorluxottica.com
- Similar Companies
- Business
- EssilorLuxottica SA designs, manufactures, distributes and retails ophthalmic lenses, eyewear frames, sunglasses and related vision care products and services worldwide. The company produces corrective and plano lenses including progressive, single-vision, photochromic and anti-reflective coatings under brands such as Varilux, Crizal, Airwear and Transitions; prescription and plano sun lenses under Xperio; branded eyewear including Ray-Ban, Oakley, Persol, Giorgio Armani, Chanel, Coach and Tiffany & Co.; optical instruments and equipment for surfacing, polishing, edging, mounting and optometry including SPECTRALIS, ANTERION and Visioffice; and med-tech solutions incorporating AI and diagnostics for eye health. Operations span over 150 countries with 47 mass production facilities, 562 prescription laboratories, 118 distribution centers and 17,638 direct-to-consumer stores and franchised locations under banners including LensCrafters, Sunglass Hut, Salmoiraghi & Viganò and GrandVision; it maintains over 50 R&D centers across the US, Europe and Asia-Pacific. Founded in 2018 through the merger of Essilor (originating in 1849) and Luxottica (founded in 1961), the company is headquartered in Charenton-le-Pont near Paris, France, with key facilities in Milan, Italy and New York. Recent developments include the 2024 extension of its long-term partnership with Meta Platforms to develop multi-generational smart eyewear such as Ray-Ban Meta glasses into the next decade; acquisitions of Heidelberg Engineering in 2024 for ophthalmic imaging, Espansione Group in 2024 for dry eye therapies, Cellview Imaging in early 2025 for retinal diagnostics, Optegra Eye Health Care in mid-2025 adding clinics across the UK, Czech Republic, Poland, Slovakia and Netherlands, RetinAI in October 2025 for AI-powered eye health therapeutics, PUcore's ophthalmic lens materials division in July 2025 pending closure by year-end, and Automation & Robotics in August 2025 for advanced manufacturing; inauguration of a new 5,000 square meter plant in Peru in late 2024 to serve Latin America; and Meta's planned acquisition of a 3% stake in 2025 amid 6% revenue growth to €26.51 billion in 2024 driven by smart eyewear success.
EssilorLuxottica: Result of the payment of dividends in shares and record of the corresponding capital increase
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026
EssilorLuxottica considered investing in Amplifon in the past, CEO says
EssilorLuxottica slips as doubts linger over smart glasses growth
EssilorLuxottica Shares Fall as Investors Weigh Impact of Smartglasses
EssilorLuxottica buys Italian tech eyewear manufacturing firm Faro
EssilorLuxottica ADR (ESLOY) Q1 2026 Sales/Trading Call Transcript
EssilorLuxottica faces test to grow smart glass sales without hurting margins
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2026
EssilorLuxottica: First-Quarter 2026 Revenue Conference Call Invitation
EssilorLuxottica acquires a stake in Top Charoen, reinforcing its presence in Thailand
Financial Comparison: Modular Medical (NASDAQ:MODD) and EssilorLuxottica (OTCMKTS:ESLOY)
Financial Survey: Glucose Health (OTCMKTS:GLUC) versus EssilorLuxottica (OTCMKTS:ESLOY)
EssilorLuxottica and Dolce&Gabbana further strengthen their partnership through 2050
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2026
NVST vs. ESLOY: Which Stock Is the Better Value Option?
EssilorLuxottica: 2025 Universal Registration Document filed
EssilorLuxottica heir seeks multibillion deal to buy out siblings, FT says
EssilorLuxottica: Disclosure of transactions in own shares